About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT02236195

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma t...

Lead sponsor: Mirati Therapeutics Inc.•14 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Mirati Therapeutics Inc.

To be eligible for this study, patient tumor testing must demonstrate a genetic alteration resulting in the loss of function of the Histone Acetyltransferase (HAT) family genes, CREBBP and/or EP300, including gene deletions or selected inactivating mutations. If testing has not already been performed, the study will provide for the testing.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of urothelial carcinoma
•Metastatic or locally advanced disease
•Prior chemotherapy that included a platinum agent
•Test results showing genetic change in tumor gene for CREBBP and/or EP300
•At least one tumor that can be measured

Exclusion Criteria

•Uncontrolled tumor in the brain
•Impaired heart function

Related studies

RECRUITINGPhase 2

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

NCT06682728 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer

RECRUITINGPhase 2

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

NCT07241793 · Urothelial Carcinoma, Advanced Urothelial Carcinoma, and more

Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity

NCT06806059 · Urothelial Carcinoma Bladder

Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

NCT05889195 · Urothelial Carcinoma

RECRUITINGPhase 3

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

NCT06857175 · Urothelial Carcinoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 1, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment17

Start dateOct 2014

Last updatedSep 1, 2017

Condition

Urothelial Carcinoma

Locations shown

University of Alabama

Birmingham, Alabama

City of Hope National Medical Center

Duarte, California

Florida Cancer Specialists

Fort Myers, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 1, 2017Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions